An Open Label, Multicenter Study, Evaluating the Imaging Characteristics of a Follow-up 18F-AV-1451 Scan in Subjects Who Have Had a Prior 18F-AV-1451 Scan
Phase of Trial: Phase II
Latest Information Update: 13 Feb 2017
At a glance
- Drugs Flortaucipir F 18 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use
- Sponsors Avid Radiopharmaceuticals
- 08 Feb 2017 Status changed from recruiting to completed.
- 08 Apr 2015 Planned End Date changed from 1 Apr 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov record.
- 08 Apr 2015 Planned primary completion date changed from 1 Apr 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov record.